Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2351

Sort by

Sort Order Select

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

Yin Yuan, Stephen Boyle

Blood (2021) 137 (23): 3310.

https://doi.org/10.1182/blood.2021011357

Published: 2021

Journal Articles

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Chloé Friedrich, Sylvain Barreau

Blood (2020) 136 (1): 148.

https://doi.org/10.1182/blood.2020005728

Published: 2020

Journal Articles

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Hisham Abdel-Azim, Christopher C. Dvorak, MD, Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS,MD, Mitchell S Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD PhD, Michael A. Pulsipher, MD

Blood (2019) 134 (Supplement_1): 4624.

https://doi.org/10.1182/blood-2019-131706

Published: 2019

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Jonathan C Poe, PhD, Dadong Zhang, PhD, Jichun Xie, PhD, Rachel A. DiCioccio, BS, Xiaodi Qin, MS, Jiyuan Fang, MS, Vincent T. Ho, MD, Jeremy J. Rose, MS, Steven Z. Pavletic, MD MS, Frances T. Hakim, PhD, Wei Jia, MD PhD, Amy N. Suthers, PhD, Mitchell E. Horwitz, MD, David A. Rizzieri, MD, William C. McManigle, MD, Nelson J. Chao, MD, Kouros Owzar, PhD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 874.

https://doi.org/10.1182/blood-2019-130928

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Longitudinal Tracking of Acute Myeloid Leukemia Stem Cells in Xenografts and Patients By microRNA Reporters and Single Cell RNA Sequencing

Matteo Maria Naldini, Gabriele Casirati, MD, Matteo Barcella, PhD, Stefano Beretta, PhD, Ivan Merelli, PhD, Carolina Caserta, Giacomo Desantis, PhD, Francesca Pavesi, MD, Fabio Ciceri, MD, Bernhard Gentner, MD

Blood (2019) 134 (Supplement_1): 916.

https://doi.org/10.1182/blood-2019-131167

Published: 2019

Journal Articles

Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL

Anneke D. van Dijk, BS, Fieke W Hoff, BSc, Yihua Qiu, Mary Figueroa, BS, Joya Chandra, PhD, Elias Jabbour, MD, Eveline S. de Bont, MD PhD, Steven M. Kornblau, MD

Blood (2019) 134 (Supplement_1): 1460.

https://doi.org/10.1182/blood-2019-124960

Published: 2019

Journal Articles

A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults

Blood (2019) 134 (Supplement_1): 1400.

https://doi.org/10.1182/blood-2019-130810

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 1312.

https://doi.org/10.1182/blood-2019-131998

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

https://doi.org/10.1182/blood-2019-127881

Published: 2019

Journal Articles

AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction

Jana Ihlow, MD, Sophia Gross, Leonie Busack, Alma Herneth, Igor-Wolfgang Blau, MD PhD, Ioannis Anagnostopoulos, MD, Michaela Schwarz, MD, Anne Floercken, MD, Lars Bullinger, MD, Jörg Westermann, MD

Blood (2019) 134 (Supplement_1): 1324.

https://doi.org/10.1182/blood-2019-127174

Published: 2019

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

https://doi.org/10.1182/blood-2019-128178

Published: 2019

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings

Giulia Borella, Ambra Da Ros, Elena Porcù, PhD, Claudia Tregnago, PhD, Maddalena Benetton, Valeria Bisio, PhD, Elisabetta Campodoni, Silvia Panseri, PhD, Monica Sandri, PhD, Monica Montesi, PhD, Stefano Cairo, PhD, Franco Locatelli, MD PhD, Martina Pigazzi, PhD

Blood (2019) 134 (Supplement_1): 544.

https://doi.org/10.1182/blood-2019-128382

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Longitudinal Tracking of Acute Myeloid Leukemia Stem Cells in Xenografts and Patients By microRNA Reporters and Single Cell RNA Sequencing

Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL

A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

AML: Negative Prognostic Impact of Early Blast Persistence Can be Overcome By Subsequent Remission Induction

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only